Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct 31;8(62):104706-104716.
doi: 10.18632/oncotarget.22218. eCollection 2017 Dec 1.

Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease

Amanda Jimenez #  1   2 , Jordi Pegueroles #  3   4 , María Carmona-Iragui  3   4 , Eduard Vilaplana  3   4 , Victor Montal  3   4 , Daniel Alcolea  3   4 , Laura Videla  3   5 , Ignacio Illán-Gala  3   4 , Adriana Pané  1 , Anna Casajoana  6 , Olivia Belbin  3   4 , Jordi Clarimón  3   4 , Violeta Moizé  1   2 , Josep Vidal  1   2   7 , Alberto Lleó  3   4 , Juan Fortea  3   4 , Rafael Blesa  3   4 ; Alzheimer's Disease Neuroimaging Initiative
Affiliations

Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease

Amanda Jimenez et al. Oncotarget. .

Abstract

Weight loss has been proposed as a sign of pre-clinical Alzheimer Disease (AD). To test this hypothesis, we have evaluated the association between longitudinal changes in weight trajectories, cognitive performance, AD biomarker profiles and brain structure in 363 healthy controls from the Alzheimer´s Disease Neuroimaging Initiative (mean follow-up 50.5±30.5 months). Subjects were classified according to body weight trajectory into a weight loss group (WLG; relative weight loss ≥ 5%) and a non-weight loss group (non-WLG; relative weight loss < 5%). Linear mixed effects models were used to estimate the effect of body weight changes on ADAS-Cognitive score across time. Baseline CSF tau/AΔ42 ratio and AV45 PET uptake were compared between WLG and non-WLG by analysis of covariance. Atrophy maps were compared between groups at baseline and longitudinally at a 2-year follow-up using Freesurfer. WLG showed increased baseline levels of cerebrospinal fluid tau/AΔ42 ratio, increased PET amyloid uptake and diminished cortical thickness at baseline. WLG also showed faster cognitive decline and faster longitudinal atrophy. Our data support weight loss as a non-cognitive manifestation of pre-clinical AD.

Keywords: Gerotarget; PET amyloid; cerebrospinal fluid Alzheimer’s disease biomarkers; magnetic resonance imaging; pre-clinical Alzheimer’s disease; weight loss.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST All authors report no biomedical financial interests or potential conflicts of interest related to this work.

Figures

Figure 1
Figure 1. Flowchart showing the samples used in this work and the subsets utilized for analyses
Figure 2
Figure 2. Observed means (SEM) differences in Alzheimer's Disease Scale Assessment
Scores according to body weight trajectory groups. In blue is represented the ADAS-Cog trajectory for the non-WLG throughout time and in red is represented the ADAS-Cog trajectory for the WLG throughout time. Dots represent mean of each time-point for both groups and the error bars show the standard error of each time-point for both groups. In the lower panel it is shown the number of observation per year.
Figure 3
Figure 3. Group comparison of the structural changes between the weight loss group (WLG) and non-weight loss group (non-WLG)
A1. Baseline differences in cortical thickness between the weight loss group (WLG) and the non-weight loss group (non- WLG). Blue areas represent significant cortical thinning in the WLG respect to the non-WLG (FWE < 0.05). A2. Box and whisker plots showing the cortical thickness for each group at the maximum significant vertex in the right temporal cluster. B1. Differences in the symmetrized percent change (spc) over the 2-year follow-up between WLG and non-WLG. Blue indicates significant increased cortical atrophy (i.e., less spc) in the WLG (FWE < 0.05). B2. Box and whisker plots showing the symmetrized percent change for each group at the maximum significant vertex in the right frontal cluster. The colors in the box-plots are only for illustrative purposes.
See this image and copyright information in PMC

References

    1. Ingram DD, Mussolino ME. Weight loss from maximum body weight and mortality: the Third National Health and Nutrition Examination Survey Linked Mortality File. Int J Obes. 2010;34:1044–50. - PubMed
    1. Pizzato S, Sergi G, Bolzetta F, De Rui M, De Ronch I, Carraro S, Berton L, Orr E, Imoscopi A, Perissinotto E, Coin A, Manzato E, Veronese N. Effect of weight loss on mortality in overweight and obese nursing home residents during a 5-year follow-up. Eur J Clin Nutr. 2015;69:1113–18. - PubMed
    1. Albanese E, Taylor C, Siervo M, Stewart R, Prince MJ, Acosta D. Dementia severity and weight loss: a comparison across eight cohorts. The 10/66 study. Alzheimers Dement. 2013;9:649–56. - PMC - PubMed
    1. Gillette-Guyonnet S, Nourhashemi F, Andrieu S, de Glisezinski I, Ousset PJ, Riviere D, Albarede JL, Vellas B. Weight loss in Alzheimer disease. Am J Clin Nutr. 2000;71:637S–42S. - PubMed
    1. White H, Pieper C, Schmader K. The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis. J Am Geriatr Soc. 1998;46:1223–27. - PubMed

LinkOut - more resources